FindMyKOL

Kamonkiat Wirunsawanya, MD

Basic profile

University of Hawaiʻi at Mānoa

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionHonolulu, HI · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Kamonkiat Wirunsawanya is an Endocrinology/Metabolic physician affiliated with University of Hawaiʻi at Mānoa. OpenAlex indexes 21 publications with 397 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
21publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

397citations

Citations across these publications.

6h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
7companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Esperion Therapeutics, Inc.
    Program year20251 payment
    $121
  • Amgen Inc.
    Program year20251 payment
    $115
  • Mannkind Corporation
    Program year20251 payment
    $69
All 10 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    40.2%
    RANK Ligand Inhibitor38.9%
    Denosumab97%Prolia3%
    Part D + Part B≥29 patients
    Bisphosphonates0.9%
    Risedronate Sodium100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    26.8%
    GLP-1 receptor agonist10.9%
    Ozempic67%Mounjaro17%Rybelsus10%Trulicity6%
    Part D≥74 patients
    Insulin Analog4.4%
    Lantus Solostar42%Novolog Flexpen28%Humalog Kwikpen U-10012%Tresiba Flextouch U-10010%Insulin Lispro Kwikpen U-1007%
    Part D<11 patients

    + 9 more classes in this area

  • Hormonal (systemic)

    20%
    l-Thyroxine14.9%
    Levothyroxine Sodium72%Synthroid28%
    Part D≥120 patients
    Thyroid Hormone Synthesis Inhibitor3.7%
    Methimazole100%
    Part D≥43 patients

    + 3 more classes in this area

Where care is delivered (Part B)17.2% facility · 82.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”